Impact of CYP2A6 and CHRM3 genetic polymorphisms on the PK/PD of pilocarpine in Japanese healthy volunteers

Impact of CYP2A6 and CHRM3 genetic polymorphisms on the PK/PD of pilocarpine in Japanese healthy volunteers - Impact of CYP2A6 and CHRM3 polymorphisms on the PK/PD of pilocarpine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010796

Enrollment

Registered

2013-05-24

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sjogren&#39

Interventions

single oral administration of pilocarpine. salagen (KISSEI PHARMACEUTICAL CO.,LTD.) 5mg 1Tablet.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy Japanese adult volunteers. BMI lower limit is 17kg/m2 BMI upper limit is 28kg/m2

Exclusion criteria

Exclusion criteria: Hepatic dysfunction (AST <50IU/L, ALT >50IU/L) Renal dysfunction (eGFR <80mL/min/1.73m2) Smoker Pregnant woman

Design outcomes

Primary

Measure	Time frame
The amount of saliva after pilocarpine administration	—

Secondary

Measure	Time frame
The blood concentration of pilocarpine	—

Countries

Japan

Contacts

Public ContactHajime Hamasaki

Oita University Faculty of Medicine Department of Clinical Pharmacology & Therapeutics

rinyaku@oita-u.ac.jp097-586-5952

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026